Skip to Main Content

Author Details

Evgeny Arons
National Cancer Institute
1996
31
16
PMIDPaper TitleJournal TitlePublished Year
36108341Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.Blood2023
36108341Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.Blood2023
37729613COVID-19 in patients with classic and variant hairy cell leukemia.Blood Adv2023
37877800Characterization of B-cell receptor clonality and immunoglobulin gene usage at multiple time points during active SARS-CoV-2 infection.J Med Virol2023
37877800Characterization of B-cell receptor clonality and immunoglobulin gene usage at multiple time points during active SARS-CoV-2 infection.J Med Virol2023
37729613COVID-19 in patients with classic and variant hairy cell leukemia.Blood Adv2023
34535326Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues.Blood Rev2022
35835913Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries.Nat Genet2022
34535326Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues.Blood Rev2022
35835913Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries.Nat Genet2022
34607348Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant.Blood Adv2021
34607348Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant.Blood Adv2021
32109194Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.J Clin Oncol2020
32109194Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.J Clin Oncol2020
32040482Expression of the muscle-associated gene MYF6 in hairy cell leukemia.PLoS One2020
32040482Expression of the muscle-associated gene MYF6 in hairy cell leukemia.PLoS One2020
31077558Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia.Cytometry B Clin Cytom2019
31077558Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia.Cytometry B Clin Cytom2019
30801054Generation of antibody-based therapeutics targeting the Idiotype of B-cell Malignancies.Antib Ther2019
30801054Generation of antibody-based therapeutics targeting the Idiotype of B-cell Malignancies.Antib Ther2019
29742076Update on hairy cell leukemia.Clin Adv Hematol Oncol2018
29742076Update on hairy cell leukemia.Clin Adv Hematol Oncol2018
26520623Impact of telomere length on survival in classic and variant hairy cell leukemia.Leuk Res2015
26520623Impact of telomere length on survival in classic and variant hairy cell leukemia.Leuk Res2015
24241536High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias.Nat Genet2014
24241536High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias.Nat Genet2014
24931452Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome.Br J Haematol2014
24697238The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.Br J Haematol2014
24931452Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome.Br J Haematol2014
24697238The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.Br J Haematol2014
24097860Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.Clin Cancer Res2013
24097860Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.Clin Cancer Res2013
24277451Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.Clin Cancer Res2013
24277451Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.Clin Cancer Res2013
22210875Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.Blood2012
22210875Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.Blood2012
21463128Response of hairy cell leukemia to bendamustine.Leuk Lymphoma2011
21463128Response of hairy cell leukemia to bendamustine.Leuk Lymphoma2011
21368287Evidence of canonical somatic hypermutation in hairy cell leukemia.Blood2011
21599610Molecular variant of hairy cell leukemia with poor prognosis.Leuk Lymphoma2011
21599609Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.Leuk Lymphoma2011
21599610Molecular variant of hairy cell leukemia with poor prognosis.Leuk Lymphoma2011
21599609Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.Leuk Lymphoma2011
21368287Evidence of canonical somatic hypermutation in hairy cell leukemia.Blood2011
19745070VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.Blood2009
19745070VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.Blood2009
18295331PRAME expression in hairy cell leukemia.Leuk Res2008
18295331PRAME expression in hairy cell leukemia.Leuk Res2008
17462732Immunoglobulin light chain repertoire in hairy cell leukemia.Leuk Res2007
17462732Immunoglobulin light chain repertoire in hairy cell leukemia.Leuk Res2007
  • 1 - 50 of 62

Recommended Authors

Panagiotis Baliakas
Uppsala University
Career Start Year 2012
Number of shared co-authors 0
Xiaoqiong Wang
The University of Texas MD Anderson Cancer Center
Career Start Year 2011
Number of shared co-authors 1
Gareth P Gregory
School of Clinical Sciences at Monash Health, Monash University
Career Start Year 2011
Number of shared co-authors 0
David Wu
University of Washington
Career Start Year 2010
Number of shared co-authors 0
Sameer A Parikh
Mayo Clinic
Career Start Year 2010
Number of shared co-authors 2
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 0
Stephen E Spurgeon
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 2006
Number of shared co-authors 0
Rashmi Kanagal-Shamanna
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 1
Michael Gombert
Hematology and Clinical Immunology, Heinrich-Heine University Dusseldorf
Career Start Year 2004
Number of shared co-authors 0
Susan Geyer
Division of Clinical Trials and Biostatistics, Mayo Clinic
Career Start Year 2001
Number of shared co-authors 1
Trang Le
KTH - Royal Institute of Technology
Career Start Year 2000
Number of shared co-authors 0
Guang Fan
Oregon Health and Science University
Career Start Year 2000
Number of shared co-authors 0
Andrew M Evens
Rutgers Robert Wood Johnson Medical School
Career Start Year 1998
Number of shared co-authors 1
David M Weinstock
Merck & Co.
Career Start Year 1998
Number of shared co-authors 0
Francisco Vega
The University of Texas MD Anderson Cancer Center
Career Start Year 1996
Number of shared co-authors 0
Jean Soulier
University of Paris
Career Start Year 1993
Number of shared co-authors 0
Christopher D Gocke
Johns Hopkins University School of Medicine
Career Start Year 1992
Number of shared co-authors 4
Arndt Borkhardt
Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf
Career Start Year 1992
Number of shared co-authors 1
Laura Z Rassenti
University of California San Diego
Career Start Year 1985
Number of shared co-authors 3
Giorgio Inghirami
Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital
Career Start Year 1984
Number of shared co-authors 0
Louis M Staudt
National Cancer Institute, National Institutes of Health
Career Start Year 1983
Number of shared co-authors 7
David M Dorfman
Brigham and Women's Hospital and Harvard Medical School
Career Start Year 1982
Number of shared co-authors 0
Sherrie L Perkins
University of Utah
Career Start Year 1982
Number of shared co-authors 2
Elias Campo
Institute for Biomedical Research August Pi I Sunyer
Career Start Year 1981
Number of shared co-authors 4
Ulrich D??hrsen
University Hospital Essen, University of Duisburg-Essen
Career Start Year 1979
Number of shared co-authors 0
Stefania Pittaluga
National Cancer Institute, National Institutes of Health
Career Start Year 1979
Number of shared co-authors 10
Riccardo Dalla-Favera
Institute for Cancer Genetics, Columbia University
Career Start Year 1978
Number of shared co-authors 0
Thomas J Kipps
University of California San Diego
Career Start Year 1977
Number of shared co-authors 3
Robin Fo??
Sapienza University.
Career Start Year 1968
Number of shared co-authors 0

Collaborators

Robert J Kreitman
National Cancer Institute
Co-authored papers 28
Maryalice Stetler-Stevenson
National Cancer Institute, National Institutes of Health
Co-authored papers 15
Mark Raffeld
Center for Cancer Research, National Cancer Institute
Co-authored papers 7
Seth M Steinberg
Center for Cancer Research, National Cancer Institute
Co-authored papers 4
Laura Roth
Martin-Luther University Halle/Wittenberg
Co-authored papers 3
Paul S Meltzer
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 3
Joel C Sunshine
Co-authored papers 2
David J Liewehr
Center for Cancer Research
Co-authored papers 2
Farhad Ravandi
University of Texas M.D. Anderson Cancer Center
Co-authored papers 2
Daniel C Edelman
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 2
Yonghong Wang
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 2
Lisa Mirabello
National Cancer Institute
Co-authored papers 1
Ogan D Abaan
Illumina Inc.
Co-authored papers 1
Hogune Im
Genome Opinion Inc.
Co-authored papers 1
Jennifer A Pacheco
University of Pennsylvania
Co-authored papers 1
Gregory S Barsh
HudsonAlpha Institute for Biotechnology, Stanford University
Co-authored papers 1
Stephen J Chanock
National Cancer Institute, National Institutes of Health
Co-authored papers 1
Daniel J Rader
Co-authored papers 1
Leslie G Biesecker
National Human Genome Research Institute, National Institutes of Health
Co-authored papers 1
Robert L Walker
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 1
Kenneth B Miller
Tufts Medical Center
Co-authored papers 1
David L Boyle
Co-authored papers 1
Gary S Firestein
Co-authored papers 1
Anurag Verma
Corporal Michael J Crescenz VA Medical Center Philadelphia
Co-authored papers 1
Jonathan K Killian
From Foundation Medicine
Co-authored papers 1
Marbin Pineda
Center for Cancer Research, National Cancer Institute
Co-authored papers 1
Sean Davis
Johns Hopkins School of Medicine, National Cancer Institute, Princeton University, University of Colorado Anschutz Medical Campus, University of Pittsburgh, University of Washington
Co-authored papers 1
Marylyn D Ritchie
Center for Systems Genomics, Pennsylvania State University, University Park
Co-authored papers 1
Meredith Yeager
Frederick National Laboratory for Cancer Research
Co-authored papers 1
Susan R Davis
Co-authored papers 1
Release 1.2